KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 89 filers reported holding KEROS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,925,104 | -29.5% | 3,604,928 | -11.2% | 0.01% | -28.6% |
| Q2 2023 | $163,092,266 | -52.9% | 4,059,041 | -49.9% | 0.01% | -12.5% |
| Q1 2023 | $346,029,954 | +95.9% | 8,103,746 | +120.3% | 0.02% | -11.1% |
| Q4 2022 | $176,669,854 | +21.6% | 3,679,089 | -4.8% | 0.02% | +20.0% |
| Q3 2022 | $145,346,000 | +46.1% | 3,863,526 | +7.3% | 0.02% | +50.0% |
| Q2 2022 | $99,465,000 | -39.2% | 3,599,895 | +19.7% | 0.01% | -23.1% |
| Q1 2022 | $163,571,000 | -20.2% | 3,007,936 | -14.2% | 0.01% | -13.3% |
| Q4 2021 | $205,066,000 | +48.1% | 3,504,798 | +0.1% | 0.02% | +36.4% |
| Q3 2021 | $138,487,000 | -6.7% | 3,500,679 | +0.2% | 0.01% | -8.3% |
| Q2 2021 | $148,413,000 | -17.7% | 3,494,539 | +19.3% | 0.01% | -20.0% |
| Q1 2021 | $180,226,000 | -3.4% | 2,928,117 | +10.7% | 0.02% | -11.8% |
| Q4 2020 | $186,551,000 | +170.4% | 2,644,620 | +47.9% | 0.02% | +142.9% |
| Q3 2020 | $68,984,000 | +35.3% | 1,788,545 | +31.5% | 0.01% | +16.7% |
| Q2 2020 | $51,001,000 | – | 1,359,672 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |